Dr. Begna on Recent Advancements in MPNs

Kebede H. Begna, MD
Published: Tuesday, May 16, 2017



Kebede H. Begna, MD, assistant professor of Medicine, Mayo Clinic, discusses some of the recent advancements in the field of myeloproliferative neoplasms (MPNs).

The advancements have mainly been in terms of diagnosis, Begna explains. Over the last several years, molecular abnormalities have been identified that are thought to be targeted with therapies, including JAK2V6171 and CALR as described in patients with myelofibrosis and essential thrombocytopenia.

Also recently, next-generation sequencing is helping physicians to define more molecular abnormalities, especially regarding prognosis of patients with myelofibrosis. This is a way to help physicians advise patients what direction to go in terms of their treatment. 
 
SELECTED
LANGUAGE


Kebede H. Begna, MD, assistant professor of Medicine, Mayo Clinic, discusses some of the recent advancements in the field of myeloproliferative neoplasms (MPNs).

The advancements have mainly been in terms of diagnosis, Begna explains. Over the last several years, molecular abnormalities have been identified that are thought to be targeted with therapies, including JAK2V6171 and CALR as described in patients with myelofibrosis and essential thrombocytopenia.

Also recently, next-generation sequencing is helping physicians to define more molecular abnormalities, especially regarding prognosis of patients with myelofibrosis. This is a way to help physicians advise patients what direction to go in terms of their treatment. 
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Community Practice Connections: Precision Medicine Through Plasma: Using Liquid Biopsies in Contemporary Oncology CareJan 31, 20191.5
Publication Bottom Border
Border Publication
x